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Abstract
Objective—To assess the association of subsequent pregnancy with subsequent metabolic 
syndrome and type II diabetes mellitus after a pregnancy complicated by mild gestational diabetes 
mellitus (GDM).
Methods—We conducted a prospective observational follow up study of women with mild GDM 
randomized from 2002–2007 to usual care or dietary intervention and glucose self-monitoring. 
Women were evaluated 5–10 years after the parent study. Participants were grouped according to 
the number of subsequent pregnancies (Group A, none [reference]; Group B, one; Group C, ≥ 
two). Serum triglycerides, glucose tolerance, HDL-cholesterol, blood pressure, and waist 
circumference were assessed. Metabolic syndrome was diagnosed by American Heart Association 
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and National Heart Lung and Blood Institute criteria. Multivariable regression was used to 
estimate adjusted relative risks (RR) and 95% confidence intervals (CI).
Results—Of 905 eligible women from the original trial, 483 agreed to participate, 426 of whom 
were included in this analysis. Groups A, B, and C consisted of 212, 143, and 71 women, 
respectively. Of women with subsequent pregnancies, 32% (69/214) had another pregnancy 
complicated with GDM. No difference between groups was observed for metabolic syndrome 
(Group A, 34%; Group B, 33%; Group C, 30%). Subsequent pregnancies were associated with 
diabetes mellitus outside of pregnancy (Group A, 5.2%; Group B, 10.5%, RR 2.62, 95%CI 1.16–
5.91; Group C, 11.3%, RR 2.83, 95%CI 1.06–7.59), and if complicated with GDM (no subsequent 
GDM pregnancy, RR 1.99, 95%CI 0.82–4.84; subsequent GDM pregnancy, RR 3.75, 95%CI 
1.60–8.82).
Conclusions—In women with prior mild GDM, subsequent pregnancies did not increase the 
frequency of metabolic syndrome, but subsequent pregnancies with GDM increased the risk of 
diabetes mellitus outside of pregnancy.
INTRODUCTION
Hormonally mediated physiologic adaptations that occur during pregnancy, including 
increased insulin resistance, weight gain, atherogenic dyslipidemia, and inflammation, 
unmask a woman’s predisposition to subsequent chronic diseases1–3. Women who develop 
gestational diabetes mellitus (GDM), for example, are known to be at increased risk of 
developing type II diabetes and cardiometabolic disorders, including metabolic syndrome4. 
Because it can often be diagnosed in a relatively short follow-up interval after pregnancy, 
and because it is associated with increased cardiovascular and metabolic disease risks, the 
diagnosis of metabolic syndrome in women who have experienced the aforementioned 
pregnancy complications has also been considered as a proxy for subsequent 
cardiometabolic disease5–6.
Pregnancy complications and their associated future diseases share common 
pathophysiologies of inflammation and endothelial dysfunction7–8. If the pregnancy-
associated changes play an etiologic role in subsequent cardiometabolic disease, we 
hypothesized that additional pregnancies occuring after a prior diagnosis of GDM, might 
increase the likelihood of subsequent metabolic syndrome.
The objective of this analysis was to assess the association of subsequent pregnancy with 
maternal cardiometabolic disorders at 5 – 10 years after an index pregnancy complicated by 
mild GDM.
MATERIALS AND METHODS
Women enrolled from October 2002 through mid-November 2007 in the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development Maternal-Fetal 
Medicine Units (MFMU) Network’s Mild GDM trial were followed up 5–10 years later 
from February 2012 through September 2013. Details regarding the parent study have been 
previously described9. Mild GDM was defined with a 3-hour 100-gram oral glucose 
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tolerance test (OGTT) with a fasting glucose of less than 95 mg/dl but two of three timed 
measurements that exceeded established thresholds: one hour, 180 mg/dl: two hour, 155 
mg/dl: and three hour, 140 mg/dl. Women did not have a prior history of pregestational or 
gestational diabetes mellitus, renal or cardiovascular disease or chronic hypertension, nor did 
they have preeclampsia at the time of enrollment in the original study. The mild GDM trial 
was approved by the institutional review board of all participating centers.
The prospective observational follow-up study10, which was not planned at the time of the 
original study, was approved by the Institutional Review Boards of all participating centers. 
Eligibility included enrollment in the original GDM study at a center still participating in the 
MFMU Network at the time of the follow-up study (12 of 16 centers throughout the United 
States; 94% of the original trial patients), and the woman’s index child participated in the 
follow-up study. Following informed consent, women underwent anthropometric and blood 
pressure measurements, and were queried about breastfeeding during the index pregnancy, 
pregnancies since their index pregnancy, medication use, physical activity, and diet. After an 
8-hour fast, participants had their blood drawn, followed by a 2-hour 75-g oral glucose-
tolerance test. Collection, processing and storage of specimens were conducted per a 
standardized approach prior to being shipped on dry ice to the Northwest Lipid Metabolism 
and Diabetes Research Laboratories for lipid panel and glucose laboratory measurements. 
Weight and height were measured using a hospital grade scale and a stationary stadiometer, 
respectively. Waist circumference was measured by trained personnel who received 
standardized anthropometric training, using an AcuFitness MyoTape just above the 
uppermost lateral border of the right ilium of the pelvis11, and an average of three 
measurements was used in the analysis. Blood pressure was measured by trained personnel 
after the participant had not smoked or consumed coffee or alcohol for at least 30 minutes, 
and was sitting quietly for at least 10 minutes, by auscultation using aneroid 
sphygmomanometer instruments or a hospital grade blood pressure–pulse machine, and an 
average of two measurements was used in the analysis. To minimize bias, research staff 
involved in data collection and laboratory analyses were masked to the participant’s 
exposures during the original study.
The primary outcome, metabolic syndrome, was defined per the American Heart 
Association and National Heart Lung and Blood Institute Scientific Statement as three or 
more of the following: high waist circumference (>88 cm), high triglycerides (≥150 mg/dL), 
low high-density lipoprotein cholesterol (HDL-C) (<50 mg/dL), blood pressure ≥130/85 
mmHg, or fasting glucose ≥100 mg/dL, or relevant treatment for any of these components12. 
Diabetes mellitus outside of pregnancy was a secondary outcome and was defined as 
currently treated for diabetes with an oral agent or insulin or meeting American Diabetes 
Association diagnostic criteria for an abnormal 75-gram glucose tolerance test13. The 
primary exposure was the number of subsequent pregnancies since the index pregnancy and 
a secondary exposure was number of subsequent pregnancies that were, or were not, 
complicated with GDM.
Descriptive analyses used the chi-square test for categorical variables and the Kruskal-Wallis 
test for continuous variables. Components of the metabolic syndrome, OGTT results, and C-
peptide were evaluated as continuous outcomes by constructing least squares means based 
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on linear multivariable regression. Metabolic syndrome, diabetes mellitus outside of 
pregnancy, and binomial components of metabolic syndrome were evaluated as binomial 
outcomes using log-Poisson multivariable regression to estimate relative risks and 95% 
confidence intervals. The multivariable models were adjusted for race–ethnicity, mild GDM 
treatment group in the index pregnancy, pregnancy associated hypertension (gestational 
hypertension or preeclampsia) in the index pregnancy, maternal age at follow-up, current 
self-reported daily servings of vegetables other than potatoes or corn, and current log body 
mass index (BMI). Continuous variables were assessed to evaluate whether they were 
normally distributed and log-transformed when appropriate. SAS software (SAS Institute, 
Cary, NC) was used for the analyses. All tests were two-tailed and p < 0.05 was used to 
define statistical significance. No imputation for missing data was performed.
RESULTS
Of the 905 eligible women with mild GDM from the original trial, 666 (74%) were 
successfully contacted, of whom 483 women consented and participated in the follow-up 
study. The maternal baseline characteristics were generally similar between women who did 
and did not participate in the follow-up study, although a higher percentage of the non-
Hispanic white women participated in the follow-up study (Appendix 2, available online at 
http://links.lww.com/xxx). Of the 483 women who were included in the follow up, 26 were 
pregnant at the time of follow-up and 31 had missing laboratory data, leaving 426 included 
in this analysis. Of these, 212 had no subsequent pregnancies since the index pregnancy 
(Group A), 143 women had only one subsequent pregnancy (Group B) and 71 women had 
two or more subsequent pregnancies (Group C). There were 309 subsequent pregnancies 
among the 214 women in groups B and C, 8 of which were multiple gestations (twins).
Demographics of the three groups at the time of enrollment in the parent study and at the 
time of this follow-up evaluation are presented in Tables 1 and 2.. Overall, 59% of the 
participants were Hispanic. Women in Group A also had higher BMIs than did women in 
Groups B and C. There were no differences between groups in treatment group, race–
ethnicity, or frequency of pregnancy-associated hypertension during the index pregnancy. 
When including all pregnancies before and after the index pregnancies, women in Group C 
had higher median parity.
At the time of enrollment in the follow-up study, women in Group A were significantly older 
(median = 38 years) than women in Groups B (median = 35 years) and C (median = 33 
years) (p < 0.001). The interval from participation in parent study to participation in the 
follow-up study was longer for women in Group C (median = 8 years) than for women in 
Groups A or B (median for both = 7 years) (p = 0.03). There were no other significant 
differences between the groups in any other self-reported demographic information, 
smoking status, dietary intake, minutes per week of vigorous physical activity, or 
breastfeeding in the index pregnancy. Almost a third (69/214; 32%) of women with 
subsequent pregnancies (Groups B and C) had another pregnancy complicated with GDM.
Results for laboratory markers of vascular risk, by group and adjusted for various potential 
confounders, are presented in Table 3. Median unadjusted insulin concentrations were not 
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significantly different between groups, although mean adjusted insulin was highest in Group 
A. No other significant differences were observed.
The frequency of metabolic syndrome and diabetes mellitus at the time of follow-up 
evaluation was 32.9% (140/426) and 8.0% (34/426), respectively (Table 4). Among the 34 
women diagnosed with diabetes, 5 were being treated with an oral agent or insulin prior to 
the follow-up visit; the remainder (N = 29, 6.8% of all participants) were diagnosed with an 
abnormal 75-gm OGTT at the follow-up visit.
The specific components of metabolic syndrome in each Group are shown in Table 4. In all 
three Groups the diagnosis of metabolic syndrome was primarily based on waist 
circumference and low HDL cholesterol. There were no differences between the groups in 
the diagnosis of metabolic syndrome (34%, 33%, 30%, respectively; relative risks 1.15 
(95%CI 0.79–1.69) and 1.00 (0.60 – 1.68) for the second and third groups, respectively, 
compared with the first group), however there was a difference between groups in diabetes 
(5.2%, 10.5%, 11.3%, respectively; relative risks 2.62 (95%CI 1.16–5.91) and 2.83 (1.06 – 
7.59) for the second and third groups, respectively, compared with the first group. The 
association with diabetes was driven mostly by having a subsequent pregnancy complicated 
with GDM, with relative risks 1.99 (95%CI 0.82–4.84) and 3.75 (1.60 – 8.82) for 
subsequent pregnancies without or with GDM, respectively, compared with women who did 
not have subsequent pregnancies (Table 5). BMI was the one risk factor consistently 
associated with all of the outcomes evaluated.
DISCUSSION
We found that pregnancies after a diagnosis of mild GDM did not increase a woman’s risk 
of developing metabolic syndrome but were associated with an increased likelihood of 
diabetes mellitus outside of pregnancy at 5–10 years after the index pregnancy. The 
magnitude of the association with post-gestational diabetes was strongest in those having a 
subsequent pregnancy complicated with GDM. While this could be consistent with either a 
stronger genetic or an environmental predisposition to Type II diabetes, it could also 
represent confounders that were not measured in this prospective observational follow-up 
study
In women with a previous diagnosis of mild GDM, metabolic syndrome was common, being 
diagnosed in 32.9% of these women at 5–10 years. Subsequent pregnancies were not 
associated with an increased likelihood of developing metabolic syndrome at 5–10 years 
follow-up but were associated with an increased incidence of diabetes mellitus outside of 
pregnancy over the same interval. The association with diabetes was driven mostly by 
subsequent pregnancy(ies) complicated with GDM.
Women whose pregnancies are complicated by GDM are known to be at increased risk for 
subsequent metabolic syndrome and other long-term vascular disease. Several previous 
reports have identified metabolic syndrome rates in parous women with a prior diagnosis of 
GDM. Verma and colleagues evaluated 106 women with a previous diagnosis of GDM at 11 
years after delivery and identified metabolic syndrome in twenty-nine (27.2%)14. A 
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subsequent report from Denmark evaluated 481 women with a previous diagnosis of GDM 
at a median of 9.8 years (interquartile range 6.4 – 17.2 years) after delivery and diagnosed 
metabolic syndrome in 38.4% 15. Most recently, Li and colleagues reported on 1263 Chinese 
women with a previous diagnosis of GDM, with 23.8% of them having a diagnosis of 
metabolic syndrome at 1–5 years after delivery 16. These incidence figures (23.8 – 38.4 
percent) are similar to our findings (32.9%). However, none of these reports provided data 
on the number of intervening pregnancies from the index pregnancy to the time of metabolic 
syndrome diagnosis. Although we observed a high overall frequency of metabolic syndrome 
in our cohort, our data suggest that subsequent pregnancies do not increase a woman’s risk 
of developing metabolic syndrome. Our data are limited, however, by the fact that we do not 
know how many patients had metabolic syndrome at the time of the index pregnancy.
Gunderson and associates have demonstrated that waist circumference increases with each 
birth while bodyweight increased only after the first birth17. However, we did not identify 
any significant differences in waist circumference between our study groups, perhaps 
because our Group A women older less likely to be nulliparous at entry into the parent study 
but our Group C women had higher overall parity by the time of the follow-up study.
The fact that participation in the parent study was limited to women with mild GDM could 
be seen as a limitation, particularly in light of the relatively low incidence of diabetes at the 
time of follow-up. Likewise, these findings may not apply to women with GDM diagnosed 
early in pregnancy. However, our frequency of metabolic syndrome is high and consistent 
with other reports in the literature14–16. Still, our results may not be generalizable to the full 
spectrum of GDM. In addition, this is a relatively small retrospective study that reported on 
less than half (426/905) of the participants in the parent study, We can thus not exclude the 
possibility of a selection bias. A higher percentage of the non-Hispanic white women 
participated in the follow-up study. Despite this, 59% of the women included in this analysis 
were Hispanic. Another limitation of this report is the lack of metabolic syndrome data from 
both the index pregnancy and prior to the index pregnancy. Likewise, given the lack of 
contact with study participants between the parent and follow-up studies, it is not possible to 
know when women with metabolic syndrome developed the condition, specifically in 
relation to any intervening pregnancies. Lastly, our limited significant findings should be 
interpreted in the context of multiple comparisons. Strengths of this report include the parent 
study’s precise definitions of mild GDM and of metabolic syndrome components and 
diabetes in the follow-up study.
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Table 1
Demographics of Follow-up Participants at the Time of Enrollment in the Parent Study, October 2002 – 
November 200713
Characteristic Number of Pregnancies Since the Index Pregnancy P-Value*
0 (n = 212) (Group A) 1 (n = 143) (Group B) 2+ (n = 71) Group C)
Race/ethnicity 0.39
 Hispanic 133 (62.7) 82 (57.3) 36 (50.7)
 Non-Hispanic, white 60 (28.3) 48 (33.6) 25 (35.2)
 Non-Hispanic, non-white 19 (9.0) 13 (9.1) 10 (14.1)
Number of live births before the index pregnancy <0.001
 0 32 (15.1) 54 (37.8) 36 (50.7)
 1 67 (31.6) 52 (36.4) 23 (32.4)
 2+ 113 (53.3) 37 (25.9) 12 (16.9)
Treated mild GDM 111 (52.4) 75 (52.5) 41 (57.8) .71
Body mass index at enrollment (kg/m2) 30.3 (27.7–33.8) 29.1 (26.2–33.0) 28.9 (25.5–32.9) 0.03
Pregnancy associated hypertension† 22 (10.4) 12 (8.4) 10 (14.1) 0.44
Data are N (%) or median (interquartile range) unless otherwise noted.
*
Based on the chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables.
†Gestational hypertension or preeclampsia.
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Table 2
Demographic and Lifestyle Information on Participants at Follow-Up, February 2012 – September 201314.
Characteristic Number of Pregnancies Since the Index Pregnancy P-Value*
0 (n = 212) Group A) 1 (n = 143) Group B) 2+ (n = 71) Group C)
Duration of follow-up (years) 7 (6–8) 7 (6–8) 8 (6–9) 0.03
Age (years) 38 (34–42) 35 (32–39) 33 (30–36) <0.001
Marital status† 0.37
 Never married 35 (16.6) 17 (11.9) 12 (16.9)
 Divorced/widowed/separated 34 (16.1) 21 (14.7) 6 (8.5)
 Married/living with partner 142 (67.3) 105 (73.4) 53 (74.6)
Insurance 0.60
 Self-pay/uninsured 75 (35.4) 46 (32.2) 25 (35.2)
 Private 66 (31.1) 52 (36.4) 28 (39.4)
 Government-assisted 71 (33.5) 45 (31.5) 18 (25.4)
Smoking 0.77
 Never 177 (83.5) 121 (84.6) 59 (83.1)
 Past 19 (9.0) 8 (5.6) 6 (8.5)
 Current 16 (7.6) 14 (9.8) 6 (8.5)
Body mass index at follow-up (kg/m2) 28.8 (25.8–33.4) 28.0 (24.2–32.6) 28.9 (23.3–33.4) 0.15
Lunch meals outside the home per week 1 (0–2) 1 (0–2) 1 (0–2) 0.92
Dinner meals outside the home per week 1 (0–2) 1 (0–2) 1 (0–1) 0.96
Cups of sugar-sweetened beverages per day 0.3 (0.0–1.0) 0.3 (0.0–1.0) 0.3 (0.0–1.0) 0.87
Servings of vegetables‡ per day 0.7 (0.4–1.4) 1.0 (0.4–2.0) 1.0 (0.4–2.0) 0.13
Servings of fruit per day 1.0 (0.6–2.0) 1.0 (0.6–2.0) 1.0 (0.7–2.0) 0.54
Vigorous physical activity minutes per week 0 (0–0) 0 (0–30) 0 (0–60) 0.32
Ever breastfed the index pregnancy 163 (76.9) 109 (76.2) 57 (80.3) 0.79
Duration breastfed the index pregnancy (months) 4 (0–4) 5 (0–5) 4 (1–4) 0.62
Pregnancies since the index pregnancy complicated 
with gestational diabetes mellitus
§
 0 212 (100.0) 100 (69.9) 45 (63.4)
 1 0 (0.0) 43 (30.1) 17 (23.9)
 2+ 0 (0.0) 0 (0.0) 9 (12.7)
Total parity 3 (2–3) 3 (2–4) 4 (3–5) <0.001
Data are N (%) or median (interquartile range) unless otherwise noted.
*
Based on the chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables.
†
Missing in one participant.
‡Other than potatoes or corn.
§Not computed due to zero cells from lack of independence between variables.
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